Why Your Doctor Won't Prescribe You Testosterone (And Who Actually Will)

The Strange Status of Female Testosterone in US Medicine

In 2026, there is no FDA-approved testosterone product on the US market specifically indicated for women. For men, there are many — gels, pellets, intramuscular injections, intranasal preparations, subcutaneous formulations, all carrying FDA-approved male labeling. For women, the shelf is empty. This article is about why that is, what the research actually supports, and how the current workaround — compounded prescriptions and off-label use of male products — actually plays out in US practice.

This is a system-level explainer. It does not recommend testosterone therapy for any individual reader. Whether testosterone is appropriate for a specific patient is a clinical decision made by a prescribing physician after history, symptoms, and bloodwork — never from an article. What the article can do is describe the regulatory and prescribing environment honestly.

The published research evidence base for female testosterone — at least for one specific indication, hypoactive sexual desire disorder (HSDD) in postmenopausal women — is actually stronger than for many interventions that do have FDA approval. The gap between the research evidence and the regulatory status is part of what makes this landscape unusual.

The Intrinsa History

In the early 2000s, Procter & Gamble developed Intrinsa, a transdermal testosterone patch designed specifically for postmenopausal women with HSDD. The registration trials — INTIMATE NM1 and related studies — showed real, measurable improvements in how often women had satisfying sex and how much desire they reported — in women who had gone through surgical menopause.^[1]

The FDA Reproductive Health Drugs Advisory Committee met on December 2, 2004 to review the Intrinsa submission. The committee voted 14-3 against recommending approval. The reasoning, as recorded in the committee minutes and subsequent FDA guidance, focused primarily on concerns about long-term cardiovascular and breast safety data — those safety concerns were amplified because the WHI study had just come out, and the whole field was rethinking every form of postmenopausal hormone therapy.

The European Medicines Agency took a different view. Intrinsa received EMA approval in July 2006 for "treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy."

In 2012, Warner Chilcott (which had acquired Procter & Gamble's pharmaceutical unit) withdrew Intrinsa from the EU market for commercial reasons. The product has not been available in either the US or EU since then.

No major pharmaceutical company has since submitted a female-specific testosterone product to the FDA for approval. The commercial case is difficult — testosterone molecules are off-patent, development costs for an FDA submission run into the hundreds of millions of dollars, and the approval path is clouded by the 2004 precedent. The result is a regulatory vacuum that has now lasted more than two decades.

What Europe and Australia Do Differently

The regulatory position on female testosterone varies internationally, and the differences are instructive.

Australia. Australia approved AndroFeme, a female-specific testosterone cream, under Therapeutic Goods Administration (TGA) regulation. It is approved for use in postmenopausal women with HSDD, prescribed by physicians and dispensed through pharmacies. Australian clinicians thus have access to a product-label female testosterone formulation that US clinicians do not.

United Kingdom and EU. No currently marketed female-specific testosterone product, but a well-established off-label prescribing practice using low-dose adaptations of male-approved products (particularly testosterone gel at approximately one-tenth the male starting dose). The British Menopause Society has published guidance supporting this off-label use in postmenopausal women with HSDD not responding to estrogen therapy.

United States. No product-label female testosterone. Physicians who prescribe do so through one of two pathways: off-label use of male-approved products at reduced doses (which is legal, but imprecise at the female dose range), or prescribing compounded preparations from 503A compounding pharmacies.

The US regulatory environment thus means the same basic treatment — low-dose testosterone for a postmenopausal woman with low desire — shows up as a stocked pharmacy product abroad and as an off-label or compounded workaround here. Same medicine, different paperwork.

What the Published Research Actually Shows

The published evidence base for female testosterone, particularly for HSDD in postmenopausal women, is substantial. The most authoritative synthesis is the 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published simultaneously in multiple endocrinology journals.^[1] That statement was endorsed by the International Society for the Study of Women's Sexual Health (ISSWSH), the International Menopause Society, the Endocrine Society, NAMS (now The Menopause Society), the British Menopause Society, the Australasian Menopause Society, and several others.

The Position Statement's summary conclusions included:

- Testosterone therapy has evidence-supported benefit for HSDD in postmenopausal women, with or without concurrent estrogen therapy. - The doses used in trials put women's testosterone levels back into the range a younger woman would have naturally — not above it. - The evidence for testosterone in other indications — general wellbeing, cognitive function, bone density, cardiovascular protection — is not sufficient to support routine prescribing for those indications. - The evidence base does not support testosterone therapy for premenopausal women, because the existing trials were conducted in postmenopausal populations. - Blood testing for total testosterone, SHBG, and calculated free testosterone should be used to monitor therapy and avoid supraphysiological dosing.

The Endocrine Society's 2014 Clinical Practice Guideline (Wierman et al.) reached broadly similar conclusions, though with somewhat more conservative phrasing around routine clinical prescribing.^[2]

This is an unusual situation: an intervention with a strong international consensus statement, endorsement from multiple credentialed bodies, and no FDA-approved product in the US market. The gap between the research consensus and the regulatory status is part of the reason this category is described so differently across clinical models. See biohacker vs clinical framing in women's hormonal care for the broader context.

How Compounded Prescribing Works for Female Testosterone

In the absence of an FDA-approved female-specific product, US physicians who prescribe testosterone for women generally do so through one of these pathways:

503A compounded preparations. A licensed compounding pharmacy prepares a testosterone formulation specified by the prescribing physician for an individual patient. Typical compounded formulations include transdermal creams, transdermal gels, sublingual troches, and subcutaneous pellets. The physician specifies the strength and vehicle; the pharmacy compounds and dispenses per the individual prescription. This is a legitimate use of the 503A framework when prescribed for a specific patient after appropriate clinical evaluation.

Off-label male-approved products at reduced doses. Some physicians prescribe male-approved testosterone gels, applying a fraction of the male starting dose. This is off-label but legal. It is less commonly preferred in women's hormone optimization practice because the male products are formulated for male dose ranges, making precise low-dose titration harder than with a compounded female-specific preparation.

Pellet implantation. Subcutaneous pellets compounded to female-physiologic doses, implanted in an office procedure and releasing hormone over several months. Popular in some practices for patient convenience; less favored in others because pellet dose can't be adjusted once implanted.

The specific dose, frequency, and monitoring protocol for any individual patient is a clinical decision made by the prescribing physician, based on the patient's history, baseline bloodwork, and response. Published clinical guidelines describe ranges of practice but do not recommend uniform doses — individualization is core to responsible prescribing in this category.

Who Actually Prescribes in This Landscape

The absence of an FDA-approved female product means that prescribing capability is concentrated among physicians who have specifically sought out training and experience in female androgen therapy. In practice:

NAMS/The Menopause Society-certified menopause practitioners. Physicians who have pursued additional certification in menopause care are substantially more likely to prescribe testosterone for female HSDD than their uncertified peers. NAMS's own position now supports testosterone for HSDD, and NAMS-certified clinicians are more likely to be familiar with the published guideline.

Functional medicine and integrative medicine physicians. This group is generally comfortable with compounded and off-label prescribing and has historically served as an access point for female testosterone in the US, often before mainstream gynecology caught up.

Longevity and women's hormone optimization practices. Platforms in this category — ranging from solo clinician practices to venture-backed telehealth — typically make female testosterone a routine part of their intake and protocols. See Pepvio vs Midi Health for a comparison of two specific platforms that represent different models for this audience.

Certified sexual medicine specialists. Sexual medicine physicians certified through ISSWSH or similar bodies are fluent in the Global Consensus Statement and in the clinical management of HSDD. This subspecialty is small but highly expert in this category.

Some general gynecologists. A minority of general gynecology practices are comfortable with female testosterone prescribing, particularly in academic centers with strong menopause programs or in practices with a physician who has pursued additional training.

Most general gynecology and primary care practices do not prescribe. Surveys in the published literature have repeatedly shown that most US gynecologists do not routinely prescribe testosterone for female HSDD, citing lack of training, lack of an FDA-approved product, and liability concerns. This is not because testosterone for HSDD is contraindicated — it's because prescribing outside the FDA-approved product catalog requires additional clinical comfort and infrastructure.

The Cash-Pay Structural Reality

A structural point worth naming explicitly: female testosterone prescribing in the US is disproportionately cash-pay rather than insurance-reimbursed.

Insurance reimbursement is tied to FDA-approved labeled uses of approved products. A compounded preparation prescribed off-label for a non-FDA-approved indication often falls outside standard insurance reimbursement pathways. Some insurance plans cover compounded hormones in limited circumstances, but the default is that women pay out of pocket for the medication.

The physician visit itself may or may not be reimbursed depending on the practice model. Women's hormone optimization practices that operate on cash-pay also charge for visits directly. Insurance-accepting menopause practices may bill for visits even if the medication is uncovered.

The result is that meaningful access to female testosterone in the US is gated by whether you can afford to pay cash. This is an equity issue worth being honest about. The international precedent — Australia's TGA-approved AndroFeme, for instance — produces a very different access pattern where an approved product is available at pharmacy-dispensing scale and often reimbursed.

For readers who want to understand the broader context of women's hormonal care and how the two dominant prescribing models handle this landscape differently, see biohacker vs clinical framing in women's hormonal care.

What Would Change This

Several developments could change the US female testosterone landscape:

New FDA submission. A company could develop a female-specific testosterone product and submit for approval. This has been sporadically attempted since the Intrinsa withdrawal but has not yet succeeded in reaching approval. The commercial case remains difficult.

Reapproval pathway for existing international products. AndroFeme (Australia) is the obvious candidate. An FDA submission based on the international approval and post-marketing experience is theoretically possible.

Expanded guideline endorsement. ACOG, the American Urological Association, and other bodies whose guidelines currently treat female testosterone more cautiously could update in response to newer evidence and the existing ISSWSH / Endocrine Society consensus. Such updates tend to shift prescribing patterns over time.

Legislative or regulatory changes to compounding. FDA policy around 503A compounding is periodically revisited. Changes could either expand or restrict current compounded prescribing practice.

Until one or more of these happens, the current landscape — compounded and off-label prescribing by a subset of physicians with specific training, predominantly cash-pay, outside mainstream gynecology — will continue to define access. That's the honest structural picture as of early 2026.

Footnotes

^[1]: Davis SR, Baber R, Panay N, et al. "Global Consensus Position Statement on the Use of Testosterone Therapy for Women." Journal of Clinical Endocrinology & Metabolism, 2019; 104(10): 4660-4666. Published simultaneously in multiple endocrinology journals and endorsed by ISSWSH, IMS, the Endocrine Society, and multiple national menopause societies. ^[2]: Wierman ME, Arlt W, Basson R, et al. "Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline." Journal of Clinical Endocrinology & Metabolism, 2014; 99(10): 3489-3510. ^[3]: Buster JE, Kingsberg SA, Aguirre O, et al. "Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial." Obstetrics & Gynecology, 2005; 105(5 Pt 1): 944-952.